Literature DB >> 27533758

Effects of digitalis on mortality in a large cohort of implantable cardioverter defibrillator recipients: results of a long-term follow-up study in 1020 patients.

Julia W Erath1, Mate Vamos1, Stefan H Hohnloser2.   

Abstract

AIMS: The effects of digitalis on mortality in patients with structural heart disease are controversially discussed. We aimed to assess the effects of digitalis administration in implantable cardioverter defibrillator (ICD) recipients. METHODS AND
RESULTS: This retrospective analysis comprises 1020 consecutive patients who received an ICD at our institution and who were followed for up to 10 years (median 37 months). A total of 438 patients were receiving digitalis at the time of ICD implantation and 582 did not. Patients on digitalis were more often in atrial fibrillation and had more often a prolonged QRS duration of ≥120 ms, a severely impaired left ventricular ejection fraction, and higher New York Heart Association (NYHA) classification heart failure. Crude Kaplan-Meier analysis demonstrated significantly higher mortality in patients on digitalis (HR = 2.47; 95% CI 1.87-3.25; P = 0.001). After adjustment for patient characteristics found statistically significant in adjusted Cox regression analysis (age, gender, NYHA classification, and QRS duration of ≥120 ms), a HR of 1.65 remained (95% CI 1.14-2.39; P = 0.01). Patients on digitalis died more often from cardiac arrhythmic and cardiac non-arrhythmic causes than patients not on digitalis (P = 0.04). There was no difference in mortality between patients receiving digitoxin and those receiving digoxin (HR = 1.55; 95% CI 0.74-3.25; P = 0.25).
CONCLUSION: In this large ICD patient population, digitalis use at baseline was independently associated with increased mortality even after careful adjustment for possible confounders. Digitalis should be used with great caution in this population. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; Congestive heart failure; Digitalis; ICD; Mortality

Mesh:

Substances:

Year:  2016        PMID: 27533758     DOI: 10.1093/ehjcvp/pvw008

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


  3 in total

1.  Cardiotonic Steroids Stimulate Macrophage Inflammatory Responses Through a Pathway Involving CD36, TLR4, and Na/K-ATPase.

Authors:  Yiliang Chen; Wenxin Huang; Moua Yang; Gang Xin; Weiguo Cui; Zijian Xie; Roy L Silverstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06-15       Impact factor: 8.311

2.  Digoxin-mortality: randomized vs. observational comparison in the DIG trial.

Authors:  Lukas Aguirre Dávila; Kristina Weber; Udo Bavendiek; Johann Bauersachs; Janet Wittes; Salim Yusuf; Armin Koch
Journal:  Eur Heart J       Date:  2019-10-21       Impact factor: 29.983

3.  The impact of serum concentration-guided digoxin therapy on mortality of heart failure patients: A long-term follow-up, propensity-matched cohort study.

Authors:  Balázs Muk; Máté Vámos; Péter Bógyi; Barna Szabó; Miklós Dékány; Dénes Vágány; Zsuzsanna Majoros; Tünde Borsányi; Gábor Zoltán Duray; Róbert Gábor Kiss; Noémi Nyolczas
Journal:  Clin Cardiol       Date:  2020-11-03       Impact factor: 2.882

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.